Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo

Overview of attention for article published in Arthritis Research & Therapy, February 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

news: 1 news outlet

twitter: 2 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 13 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 news story.

Tofacitinib exhibits shorter timeline to initial clinical response in PsA vs. placebo

Healio.com, 14 Mar 2022

March 14, 2022 3 min read Source/Disclosures Published by: Disclosures: This study was supported funded by Pfizer.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.